Overfill Math: Getting 22–25 Units Out of a '20-Unit' Vial Without Compromising Results

Why most of the surplus disappears

The surplus vanishes in the same place all injectable margin leaks: dead space. A standard luer-lock syringe paired with a separate draw-up needle strands product in the hub and the needle every single time — often enough to erase the overfill entirely and then some. Two transfers (draw into one needle, swap to the injection needle) doubles the loss.

So the practice that "never sees" overfill isn't unlucky. It's losing the surplus, and a chunk of the labeled units besides, to a draw-up habit that bleeds product on every patient.

Capturing it without compromising care

The recovery technique is unglamorous and entirely about minimizing dead space:

• Draw and inject with unit-marked insulin syringes that have an integrated (non-removable) needle. The fixed needle nearly eliminates hub loss, and the unit markings remove dosing guesswork.
• Aspirate the vial thoroughly — angle it, recover the last of the reconstituted volume rather than leaving a few units clinging to the stopper.
• Minimize transfers. Every time product moves between syringes or needles, you pay a dead-space tax. Fewer steps, more product.

Done well, a "20-unit" treatment plan drawn from a properly handled vial routinely yields the units you charted plus a little — and that little, captured consistently, is the overfill becoming revenue instead of waste.

The discipline that keeps it honest

There's a failure mode worth naming, because regulators and good clinicians both care about it: chasing overfill must never become a reason to under-dose. The temptation is to stretch recovered product across more area than the dose supports so the vial "goes further." That's not margin management; it's thinning treatments, and it produces weak results, unhappy patients, and a chart that doesn't match the care.

The correct sequence is fixed: dose the patient properly first, chart accurately, and treat any recovered surplus as a margin benefit — applied to the next appropriately-dosed patient, not used to justify a lighter treatment on this one.

What to do

• Standardize low-dead-space draw-up across every injector — insulin syringes with integrated needles, minimal transfers.
• Track realized units billed per vial monthly. A room capturing overfill will show units-billed-per-vial at or slightly above the labeled count; a room bleeding it will sit well below.
• Coach the difference between recovering surplus and stretching dose. Make it explicit that proper dosing is non-negotiable and surplus is a byproduct, not a target.
• Reconcile against rebates so you know your true loaded cost per billed unit — the only cost number that matters.

The overfill isn't a trick or a loophole. It's product you already own, and whether it ends up in a patient you billed or in a red bag is decided entirely by how you draw and whether you measure. Most practices never run that math. The ones that do quietly carry a cost advantage their competitors can't explain.